Creatinine–Cystatin C eGFR Discordance Identifies Long-Term Cardiorenal Risk in Acute Coronary Syndrome: A Cohort Study
Journal of Nephrology · 13.11.2026
DOI: 10.1093/joneph/aajag276 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Nephrology, online erschienen am 13.11.2026. Verfasst von Cristina García Majado und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hospital Universitario Marqués de Valdecilla-IDIVAL, RICORS2040, Av. Valdecilla s/n, Santander, Cantabria, 39008, Spain.
Abstract (Originalsprache)
Background
Discordance between creatinine- and cystatin C–based estimated glomerular filtration rate (eGFR) is common and has been associated with adverse outcomes in population-based cohorts. However, its relevance in patients with acute coronary syndrome (ACS) remains uncertain.
Methods
We conducted a retrospective cohort study including 808 patients with ACS admitted to the Cardiac Intensive Care Unit of Marqués de Valdecilla University Hospital (Santander, Spain) between 1 January, 2012 and 31 December, 2015, for whom measurements of creatinine and cystatin C at admission were available. Discordance between creatinine- and cystatin C–based eGFR was assessed using continuous indices (eGFR difference and ratio) and categorical definitions based on a threshold of 15 mL/min/1.73m². Associations with all-cause mortality, major adverse cardiovascular events (MACE), and kidney function decline were evaluated using Cox regression models adjusted for cardiovascular risk factors and creatinine–cystatin C eGFR.
Results
Creatinine–cystatin C eGFR discordance was present in 44.2% of patients. Over a median follow-up of 8.4 years, lower cystatin C–based relative to creatinine-based eGFR was associated with higher risks of all-cause mortality, MACE, and kidney function decline. These associations persisted among patients with preserved creatinine-based kidney function. In adjusted models, each 10 mL/min/1.73 m² increase in eGFR difference, indicating higher eGFRcys relative to eGFRcr, was associated with lower risks of mortality (Hazard Ratio [HR] 0.88, 95% Confidence Interval [CI] 0.80–0.96) and kidney function decline (HR 0.80, 95% CI 0.71–0.91), with a similar trend for MACE (HR 0.91, 95% CI 0.83–1.00).
Conclusions
In patients hospitalised with ACS, eGFR discordance reflecting lower cystatin C–based eGFR than creatinine-based eGFR is associated with adverse long-term cardiorenal outcomes, even among patients with preserved creatinine-based kidney function.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Hospital Universitario Marqués de Valdecilla-IDIVAL, RICORS2040, Av. Valdecilla s/n, Santander, Cantabria, 39008, Spain.
- Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla-IDIVAL, Av. Valdecilla s/n, Santander, Cantabria, 39008, Spain.
- Department of Medicine and Psychiatry, University of Cantabria, Santander, Cantabria, Spain.
ORCID-Profile: Cristina García Majado
Zitieren
APA
García Majado, C., Baldeón Conde, C., Rodrigo Calabia, E., Pasache Chong, J. E., Fernández Fresnedo, G., Ruiz, J. C., & Hernández, J. L. (2026). Creatinine–Cystatin C eGFR Discordance Identifies Long-Term Cardiorenal Risk in Acute Coronary Syndrome: A Cohort Study. Journal of Nephrology. https://doi.org/10.1093/joneph/aajag276
Vancouver
García Majado C, Baldeón Conde C, Rodrigo Calabia E, Pasache Chong JE, Fernández Fresnedo G, Ruiz JC, et al. Creatinine–Cystatin C eGFR Discordance Identifies Long-Term Cardiorenal Risk in Acute Coronary Syndrome: A Cohort Study. Journal of Nephrology. 2026. doi:10.1093/joneph/aajag276
BibTeX
@article{GarcaMajado2026,
author = {García Majado, Cristina and Baldeón Conde, Cristina and Rodrigo Calabia, Emilio and Pasache Chong, José Enrique and Fernández Fresnedo, Gema and Ruiz, Juan Carlos and Hernández, José Luis},
title = {Creatinine–Cystatin C eGFR Discordance Identifies Long-Term Cardiorenal Risk in Acute Coronary Syndrome: A Cohort Study},
journal = {Journal of Nephrology},
year = {2026},
doi = {10.1093/joneph/aajag276}
}
EUVIMED